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Abstract
Background: Previous research suggests the therapeutic cancer vaccine L-BLP25 potentially provides a survival
benefit in patients with locally advanced unresectable stage III non-small cell lung carcinoma (NSCLC). These
promising findings prompted the phase III study, INSPIRE, in patients of East-Asian ethnicity. East-Asian ethnicity is
an independent favourable prognostic factor for survival in NSCLC. The favourable prognosis is most likely due to a
higher incidence of EGFR mutations among this patient population.
Methods/design: The primary objective of the INSPIRE study is to assess the treatment effect of L-BLP25 plus best
supportive care (BSC), as compared to placebo plus BSC, on overall survival time in East-Asian patients with
unresectable stage III NSCLC and either documented stable disease or an objective response according to the
Response Evaluation Criteria in Solid Tumors (RECIST) criteria following primary chemoradiotherapy. Those in the
L-BLP25 arm will receive a single intravenous infusion of cyclophosphamide (300 mg/m
2) 3 days before the first
L-BLP25 vaccination, with a corresponding intravenous infusion of saline to be given in the control arm. A primary
treatment phase of 8 subcutaneous vaccinations of L-BLP25 930 μg or placebo at weekly intervals will be followed
by a maintenance treatment phase of 6-weekly vaccinations continued until disease progression or discontinuation
from the study.
Discussion: The ongoing INSPIRE study is the first large study of a therapeutic cancer vaccine specifically in an
East-Asian population. It evaluates the potential of maintenance therapy with L-BLP25 to prolong survival in East-
Asian patients with stage III NSCLC where there are limited treatment options currently available.
Study number: EMR 63325-012
Trial Registration: Clinicaltrials.gov reference: NCT01015443
Background
The incidence of lung cancer is high in Asia, particularly
Eastern Asia, and is on the rise. There were an estimated
873,300 new cases in Asia in 2008 and 753,800 deaths
from lung cancer that same year [1,2]. The rising inci-
dence is thought to reflect smoking behaviours among
Asian men while other factors are thought to be largely
responsible for the rise among women, including cooking
oil vapour, coal burning and outdoor air pollution [3].
Non-small cell lung cancer (NSCLC) accounts for
approximately 80-85% of all cases of lung cancer [4] and
a substantial proportion of patients with NSCLC are initi-
ally diagnosed with stage III disease [5].
Concurrent chemotherapy and radiotherapy is generally
considered the standard of care for unresectable stage III
NSCLC [6-9]. Local and distant treatment failures are
common among patients with stage III NSCLC, and the
majority die within three years of diagnosis. Chemora-
diotherapy may also be associated with substantial toxicity,
including myelosuppression, oesophagitis, nausea and
vomiting. Therapeutic progress using chemoradiotherapy
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any medium, provided the original work is properly cited.appears to have reached a plateau and therefore new treat-
ments are urgently needed [10,11].
Mucin 1 (MUC1) is a glycoprotein that was first identi-
fied as a tumour-associated antigen in the mid-1980s; it is
overexpressed and aberrantly glycosylated in many carci-
nomas including NSCLC. MUC1 can stimulate cell prolif-
eration and suppress apoptosis and therefore may have a
role in tumour progression. Moreover, abnormal MUC1
expression is associated with progressive disease and
metastasis [12,13].
BLP25 liposome vaccine or L-BLP25 (Stimuvax
®)i sa
therapeutic cancer vaccine that targets the MUC1 antigen.
A phase II study comparing L-BLP25 plus best supportive
care (BSC) with BSC alone in 171 patients with stage IIIB/
IV NSCLC reported median overall survival times of 17.4
months and 13 months, respectively, after a median fol-
low-up of 26 months (adjusted hazard ratio [HR] 0.739,
95% confidence interval [CI] 0.509-1.073, p = 0.112). The
greatest difference was observed in patients with stage IIIB
locoregional disease (n = 65) in whom the median survival
time had not been reached for the L-BLP-25 arm, com-
pared with 13.3 months for the BSC arm (adjusted HR =
0.524, 95% CI 0.261-1.052, p = 0.069) at the time of the
initial publication [14]. An updated survival analysis in the
patients with stage IIIB locoregional disease reported a
median survival time of 30.6 months with L-BLP25 vs 13.3
months in the control arm (follow up of 53 and 57
months, respectively; HR 0.548, 95% CI 0.301-0.999) [15].
On the basis of these findings, the phase III trial, START
(Stimulating Targeted Antigenic Responses To NSCLC),
was initiated. START is investigating the efficacy and
safety of L-BLP25 as maintenance therapy for unresectable
stage III NSCLC in a global population of patients from
North and South America, Europe and Australia. Recruit-
ment for the START study is expected to be completed in
2011.
Asian ethnicity has been consistently shown to be an
independent favourable prognostic factor for survival in
patients with NSCLC. Data from the FLEX study investi-
gating cetuximab plus chemotherapy versus chemotherapy
alone, and the INTEREST study of gefitinib versus doce-
taxel, indicated that Asian patients with advanced NSCLC
had longer survival compared with white patients (FLEX)
and non-Asian patients (INTEREST) [16,17]. Furthermore,
in a meta-analysis of randomised controlled trials of first-
line chemotherapy in advanced stage NSCLC, a longer
overall survival was seen in Asian compared with Cauca-
sian patients [18]. The association between Asian ethnicity
and survival is independent of smoking status and other
prognostic factors [19-21]. The likely underlying explana-
tion is a high incidence of polymorphism in the epidermal
growth factor receptor (EGFR) gene among East-Asian
populations, with a prevalence of EGFR mutations of 25-
35% compared with around 10% in other ethnic groups
[22-24]. A high level of EGFR protein may be a poor prog-
nostic factor for survival in NSCLC [25].
Because the longer median survival of Asian patients
with NSCLC could be a confounding effect in a global
trial, INSPIRE (Stimuvax trial InA s i a nNSCLC Patients:
stimulating Immune Response), was initiated in a solely
East-Asian population to complement the START trial. In
addition, a smaller study is ongoing in Japan. The INSPIRE
study will evaluate the efficacy and safety of L-BLP25 as
maintenance therapy for East-Asian patients (excluding
Japan) with unresectable stage III NSCLC. Together,
INSPIRE and START will enrol approximately 2,000
patients. Both studies have survival as the primary end-
point; progression is assessed by the investigator according
to institutional standards.
Methods/Design
Patients
All patients in the INSPIRE study have locally advanced
unresectable stage III NSCLC [26], and documented
stable disease or an objective response according to the
Response Evaluation Criteria In Solid Tumors (RECIST)
criteria following primary chemoradiotherapy (completed
from 4-12 weeks before randomization). Patients with
metastatic disease or malignant pleural effusion (MPE)
are excluded from the study. The inclusion and exclusion
criteria are summarized in Table 1. Recruitment for the
INSPIRE study is currently underway in approximately
40 trial sites in China, Hong Kong, Singapore, South
Korea, and Taiwan with a target study population of 420
patients. Written informed consent must be provided by
all patients before any trial-related activities are carried
out.
Study design and treatments
The design of the INSPIRE study is summarized in
Figure 1. INSPIRE is a double-blind, placebo-controlled,
phase III clinical trial in which patients are randomized
in a 2:1 ratio to either L-BLP25 or placebo. Randomiza-
tion to treatment is stratified by disease stage at first
diagnosis (IIIA versus IIIB), histology (adenocarcinoma
versus non-adenocarcinoma; Asian patients with adeno-
c a r c i n o m ah a v eb e e ns h o w nt oh a v eab e t t e rp r o g n o s i s
than patients with other types of histology [27]) and
type of primary chemoradiotherapy (concomitant versus
sequential). All patients will receive BSC, which may
include, but is not limited to, psychosocial support,
nutritional support and other supportive therapies.
Three days before the first L-BLP25 vaccination, a single
intravenous infusion of cyclophosphamide 300 mg/m
2
(maximum dose 600 mg) (L-BLP25 arm) or saline (control
arm) will be administered. The purpose of administering
cyclophosphamide is to inhibit Treg cells and enhance the
development of an effective response to the immunogen
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of 8 subcutaneous vaccinations of L-BLP25 930 μg or pla-
cebo at weekly intervals. L-BLP25 is composed of a lyophi-
lized preparation of the 25-amino-acid BLP25 lipopeptide,
an immunoadjuvant (monophosphoryl lipid A) and three
lipids (cholesterol, dimyristoyl phosphatidylglycerol and
dipalmitoyl phosphatidylcholine). The nominal dose of
L-BLP25 is different to that previously stated [14,29].
In clinical studies prior to 2008 the density determination
of L-BLP25 prior to freeze-drying of the final powdered
product led to the content of L-BLP25 being declared as
1000 μg. However, the more recent density determination
means that the majority of phase IIb study participants
actually received 930 μg antigen as opposed to the
1000 μg that was declared, and phase III studies including
INSPIRE continue to use the 930 μg dose. The placebo,
which is also delivered subcutaneously, is formulated to
provide the same carrier lipid matrix as the L-BLP25 vac-
cine, but without the monophosphoryl lipid A adjuvant
and BLP25 lipopeptide. L-BLP25 can be associated with
local injection site reactions; however, as these reactions
tend to be mild, and are not universal, patients and physi-
cians cannot definitively determine who receives placebo
or vaccine.
The primary treatment phase is followed by a mainte-
nance treatment phase, with vaccinations at 6-week
intervals until disease progression or discontinuation
from the study. As the investigators will evaluate disease
progression according to institutional standards, the
technique and timing of imaging will vary from site to
site. Although patients with disease progression will no
longer receive either the study medication or placebo,
where possible they will remain in the trial for the eva-
luation of the primary endpoint, overall survival time.
With the exception of the trial treatment and any neces-
sary supportive treatment, patients enrolled in the study
are not permitted drugs that are intended to modulate
the immune system or systemic immunosuppressants.
While receiving trial treatment, patients are not per-
mitted any other investigational drugs, chemotherapy or
radiotherapy.
Patients are followed up at each treatment visit during
the primary (i.e. weekly) and maintenance (i.e. every 6
weeks) treatment phases, and 6 and 12 weeks after the
last study treatment. Long-term follow-up will comprise
assessments at 12-week intervals beginning 24 weeks
after the last study treatment and continuing until death
or study end.
Table 1 Key inclusion and exclusion criteria
Inclusion
criteria
Histologically documented unresectable stage III NSCLC, with stage confirmed by imaging (CT and/or MRI and/or PET)
Completion of chemoradiotherapy (concomitant or sequential) ≥ 4 weeks and ≤ 12 weeks prior to randomization, consisting of
≥ 2 cycles of platinum-based chemotherapy and a radiation dose of ≥ 50 Gy
Stable disease or objective response after primary chemoradiotherapy according to RECIST [37] documented ≤ 4 weeks prior to
randomization
ECOG performance status of 0 or 1
Platelet count ≥ 140 × 10
9/L; WBC ≥ 2.5 × 10
9/L; haemoglobin ≥ 90 g/L
≥ 18 years of age
Exclusion
criteria
Prior therapies Lung-cancer-specific therapy (including surgery) other than primary chemoradiotherapy
Immunotherapy ≤ 4 weeks prior to randomization
Investigational systemic drugs ≤ 4 weeks prior to randomization
Disease status Metastatic disease
Malignant pleural effusion
Past or current history of neoplasm other than lung carcinoma*
Autoimmune disease or recognized immunodeficiency
Pre-existing medical conditions requiring chronic steroid or immunosuppressive drug therapy
Signs and symptoms suggestive of, or family history of, transmissible spongiform encephalopathy
Clinically significant active or chronic infectious hepatitis
Hepatic dysfunction (ALT > 2.5 × ULN, AST > 2.5 × ULN or bilirubin ≥ 1.5 × ULN)
Renal dysfunction (serum creatinine ≥ 1.5 × ULN)
Clinically significant cardiac disease
Splenectomy
*Except for curatively treated nonmelanoma skin cancer, in situ carcinoma of the cervix, or other cancer curatively treated and with no evidence of disease for at
least 5 years.
ALT: alanine aminotransferase; AST: aspartate aminotransferase; CT: computed tomography; ECOG: Eastern Cooperative Oncology Group; MRI: magnetic resonance
imaging; NSCLC: non-small cell lung cancer; RECIST: Response Evaluation Criteria In Solid Tumors; ULN: upper limit of normal; WBC: white blood cell count.
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The objectives of the study are presented in Table 2. The
primary objective of the INSPIRE study is to assess the
treatment effect of L-BLP25 plus BSC, as compared to
BSC alone, on overall survival time. Secondary objectives
include the evaluation of differences between treatment
arms in terms of time to symptom progression (based on
the Lung Cancer Symptom Scale [LCSS] questionnaire),
time to progression, progression-free survival time and
safety parameters. Adverse events of special interest in
the trial include injection-site reactions, thrombocytope-
nia, hepatic dysfunction and autoimmune disease.
Statistics
The sample size of 420 patients was chosen to allow for
the potential identification of a trend towards prolonged
survival with L-BLP25 while taking the following factors
into account: a 2:1 randomization ratio (L-BLP25 vs
control arm), an increase of median overall survival time
from 24 months in the control arm to 31 months with
L-BLP25, a linearly increasing cumulative enrolment
over 30 months and a total trial duration of 54 months
(follow-up of 24 months). Follow-up will be event-dri-
ven with analysis to take place after 211 deaths are
reported.
Primary treatment phase Maintenance treatment phase Follow-up
Maintenance treatment continued
until progressive disease
or discontinuation
Pre-treatment
evaluation
Pre-treatment
evaluation
Weeks –4 –3 –2 –1
–4 Weeks –3 –2 –1
12 3 4 5 6 7 8
1 2 3 4 5 6 7 8 14 20 26
14 20 26
3 d
R
Tumour
imaging**
GSULRUWR
randomization)
Tumour
imaging**
(according to
local hospital standards)
Cyclophosphamide
pretreatment
(300 mg/m2 [max 600 mg]
single IV infusion)
Sodium
chloride
(0.9% IV)
*Formulated to provide the same carrier lipid matrix as L-BLP25, but without the adjuvant (monophosphoryl lipid A) and BLP25 lipopeptide.
**Computed tomography and/or magnetic resonance imaging.  
Each syringe represents four SC injections of L-BLP25 or placebo at four anatomical sites 
(deltoid or triceps region of the upper arms and the left and right anterolateral aspects of the abdomen).
The syringe represents a single IV infusion of cyclophosphamide or saline substitute for cyclophosphamide.
d, days; IV, intravenous; R, randomization; SC, subcutaneous.
Control arm: placebo* SC
L-BLP25 arm: 930 μg SC
Figure 1 Study design.
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Prior to initiation of the study, each of the participating
sites must obtain local ethics committee approval from
the appropriate body. All research will conform to the
Declaration of Helsinki, as well as local legal and ethical
requirements.
Discussion
Previous research reported longer survival times with L-
BLP25 plus BSC versus BSC alone in patients with stage
IIIB/IV NSCLC, and this effect was more pronounced in
the subset of patients with stage IIIB locoregional disease
[14,15]. These findings prompted the initiation of the
START and INSPIRE studies to evaluate a potential survi-
val benefit with L-BLP25 in a larger population with stage
III NSCLC.
The most common adverse events with L-BLP25 treat-
ment are Grade 1 flu-like symptoms (such as fatigue),
minor injection site reactions (such as erythema and bruis-
ing) and adverse events related to cyclophosphamide
administration (most commonly nausea). The pattern and
incidence of adverse events does not appear to change
over time with long-term treatment [14,29-32].
In ongoing trials, events that could be suggestive of
autoimmune disease were uncommonly observed. In
March 2010 a case of encephalitis was assessed as a sus-
pected unexpected serious reaction. As a result, the clini-
cal program for L-BLP25 in all recruiting studies
worldwide was temporarily suspended. This decision was
taken in alignment with the FDA’s clinical hold placed on
the Investigational New Drug application for L-BLP25.
This case was observed in a mechanism of action study of
L-BLP25 in multiple myeloma. A potential autoimmune
causality of this case could not be excluded. Subsequent
work-up and overall safety analysis of L-BLP25 in NSCLC
led to the clinical hold being lifted and trials of L-BLP25
in NSCLC have restarted with additional safety monitoring
procedures in place, such as more frequent neurological
examinations of patients during the study and closer mon-
itoring of patients should they develop neurologic signs of
any origin.
There is an urgent need for new treatments in patients
with unresectable stage III NSCLC. With chemora-
diotherapy, 5-year survival rates for these patients are
less than 15% [33]. The populations of both the INSPIRE
and START studies are limited to patients with unresect-
able stage III disease. There is a possibility that the radio-
therapy which was received by the majority of patients
with stage IIIB locoregional NSCLC may have contribu-
ted to the benefit seen in the phase II trial of L-BLP25.
Radiotherapy induces pro-immunogenic effects that may
render tumours more responsive to subsequent immu-
notherapy [34,35]. All patients in the INSPIRE study will
have been treated with radiotherapy as well as che-
motherapy before being randomized into the study. The
control arm of the trial is reflective of the global standard
of care received by patients with stage III disease. The
placebo used in the control arm has neither the adjuvant
nor the BLP25 antigen. The adjuvant was excluded from
the placebo, given that even if the adjuvant was capable
of eliciting a non-specific immune response in the
absence of the BLP25 antigen, it is highly unlikely that
any non-specific response would lead to an improvement
in survival. As the placebo does not contain the peptide
either, the placebo is very unlikely to elicit an immune
response or influence overall survival time.
The INSPIRE study uses the 6
th edition of the staging
system published in 2002 by the Union Internationale
Contre le Cancer (UICC) and the American Joint Com-
mittee on Cancer (AJCC) [26]. In the 7
th edition, pub-
lished in 2009, malignant pleural effusion now constitutes
metastatic disease and as such is stage IV [36]. However,
this will not impact on the INSPIRE study as malignant
pleural effusion is an exclusion criterion.
The INSPIRE study, together with findings from the
smaller phase I/II study of L-BLP25 also currently
ongoing in Japan, will provide a valuable insight into the
potential role of L-BLP25 as maintenance therapy for
East-Asian patients with unresectable stage III NSCLC.
These trials, alongside the START trial, will expand sub-
stantially upon the body of knowledge for the novel ther-
apeutic cancer vaccine L-BLP25 and its clinical role in
Table 2 Study objectives
Primary objective To assess the treatment effect of L-BLP25 plus BSC, as compared to BSC alone, on overall survival time
Secondary objectives Time to symptom progression (based on LCSS questionnaire)
Time to progression
Progression-free survival time
Time to treatment failure
Safety
Other objectives Quality-of-life (EQ-5D/LCSS)
Healthcare resource utilization and work status
Biomarkers/pharmacogenetics
BSC: best supportive care; EQ-5D: EuroQol Group 5-Dimension questionnaire; LCSS: Lung Cancer Symptom Scale.
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trials will also provide preliminary data on ethnic factors
underlying the immune response to NSCLC following
receipt of a therapeutic cancer vaccine.
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